Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Randomised, Single-dose, Four-way Cross-over Formulation Finding Study of the Oral Bioavailability of Four Prototype Extended Release Formulations With 25 mg BI 11634, and Intra-individual Comparison to Immediate-release Tablets (25 mg) in Healthy Male Volunteers

NCT02214953 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02214953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02214953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Randomised, Single-dose, Four-way Cross-over Formulation Finding Study of the Oral Bioavailability of Four Prototype Extended Release Formulations With 25 mg BI 11634, and Intra-individual Comparison to Immediate-release Tablets (25 mg) in Healthy Male Volunteers
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2007
Completion date
Not reported
Enrollment
17 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy